AVMAPKI

AVMAPKI is the brand name for avutometinib, a small molecule MEK1/2 inhibitor developed by Chugai Pharmaceutical Co., Ltd. and further developed and commercialized by Verastem Oncology. It functions by blocking the RAS/RAF/MEK/ERK (MAPK) pathway, a critical signaling cascade often hyperactivated in KRAS-mutated cancers, thereby inhibiting cancer cell growth and survival. Avutometinib also prevents the compensatory reactivation of MEK by upstream RAF. It is approved in the U.S. as part of the AVMAPKI Fakzynja Co-Pack, in combination with defactinib, for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy.

Brand names

AVMAPKI

Other names

avutometinib